doi:10.19983/j.issn.2096-8493.2024114

Abstract

CLC Number:

R563
R516

Figures/Tables 3

References 24

[1]	Colombo C, Littlewood J. The implementation of standards of care in Europe: state of the art. J Cyst Fibros, 2011, 10 Suppl 2: S7-S15. doi:10.1016/s1569-1993(11)60003-9.
[2]	囊性纤维化诊断与治疗中国专家共识编写组, 中国罕见病联盟呼吸病学分会, 中国支气管扩张症临床诊治与研究联盟. 囊性纤维化诊断与治疗中国专家共识(2023版). 中华结核和呼吸杂志, 2023, 46(4): 352-372. doi:10.3760/cma.j.cn112147-20221214-00971.
[3]	Schnitker F, Liu Y, Keitsch S, et al. Reduced Sphingosine in Cystic Fibrosis Increases Susceptibility to Mycobacterium abscessus Infections. Int J Mol Sci, 2023, 24(18):14004. doi:10.3390/ijms241814004.
[4]	Bryant JM, Brown KP, Burbaud S, et al. Stepwise pathogenic evolution of Mycobacterium abscessus. Science, 2021, 372(6541):eabb8699. doi:10.1126/science.abb8699.
[5]	中华医学会结核病学分会. 非结核分枝杆菌病诊断与治疗指南(2020年版). 中华结核和呼吸杂志, 2020, 43(11): 918-946. doi:10.3760/cma.j.cn112147-20200508-00570.
[6]	时翠林, 张建平, 唐佩军, 等. 脓肿分枝杆菌肺病治疗研究进展. 中华结核和呼吸杂志, 2021, 44(3): 252-257. doi:10.3760/cma.j.cn112147-20210108-00020.
[7]	Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J, 2020, 56(1):2000535. doi:10.1183/13993003.00535-2020.
[8]	Guo X, Liu K, Liu Y, et al. Clinical and genetic characteristics of cystic fibrosis in CHINESE patients: a systemic review of reported cases. Orphanet J Rare Dis, 2018, 13(1):224. doi:10.1186/s13023-018-0968-2. pmid: 30558651
[9]	Shi R, Wang X, Lu X, et al. A systematic review of the clinical and genetic characteristics of Chinese patients with cystic fibrosis. Pediatr Pulmonol, 2020, 55(11): 3005-3011. doi:10.1002/ppul.24980.
[10]	Recchia D, Stelitano G, Stamilla A, et al. Mycobacterium abscessus Infections in Cystic Fibrosis Individuals: A Review on Therapeutic Options. Int J Mol Sci, 2023, 24(5):4635. doi:10.3390/ijms24054635.
[11]	Mauch RM, Jensen P, Qvist T, et al. Adaptive Immune Response to Mycobacterium abscessus Complex (MABSC) in Cystic Fibrosis and the Implications of Cross-Reactivity. Front Cell Infect Microbiol, 2022, 12:858398. doi:10.3389/fcimb.2022.858398.
[12]	沙巍, 梁莉, 蒋瑞华, 等. 含头孢西丁方案治疗高度耐药的快速生长型非结核分枝杆菌肺部感染16例疗效观察. 中华结核和呼吸杂志, 2011, 34(4): 265-268. doi:10.3760/cma.j.issn.1001-0939.2011.04.011.
[13]	Kwak N, Dalcolmo MP, Daley CL, et al. Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis. Eur Respir J, 2019, 54(1):1801991. doi:10.1183/13993003.01991-2018.
[14]	Kwon YS, Levin A, Kasperbauer SH, et al. Efficacy and safety of tigecycline for Mycobacterium abscessus disease. Respir Med, 2019, 158: 89-91. doi:10.1016/j.rmed.2019.10.006.
[15]	Philley JV, Wallace RJ Jr, Benwill JL, et al. Preliminary Results of Bedaquiline as Salvage Therapy for Patients With Nontuberculous Mycobacterial Lung Disease. Chest, 2015, 148(2): 499-506. doi:10.1378/chest.14-2764. pmid: 25675393
[16]	Sarathy JP, Ganapathy US, Zimmerman MD, et al. TBAJ-876, a 3,5-Dialkoxypyridine Analogue of Bedaquiline, Is Active against Mycobacterium abscessus. Antimicrob Agents Chemother, 2020, 64(4):e02404-19. doi:10.1128/aac.02404-19.
[17]	Duah M, Beshay M. Omadacycline in first-line combination therapy for pulmonary Mycobacterium abscessus infection: a case series. Int J Infect Dis, 2022, 122: 953-956. doi:10.1016/j.ijid.2022.06.061.
[18]	Rizzo AR, Moniri NH. Omadacycline for management of Mycobacterium abscessus infections: a review of its effectiveness, place in therapy, and considerations for use. BMC Infect Dis, 2022, 22(1):874. doi:10.1186/s12879-022-07857-7.
[19]	Tang YW, Cheng B, Yeoh SF, et al. Tedizolid Activity Against Clinical Mycobacterium abscessus Complex Isolates-An in vitro Characterization Study. Front Microbiol, 2018, 9: 2095. doi:10.3389/fmicb.2018.02095.
[20]	Dedrick RM, Smith BE, Cristinziano M, et al. Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease. Clin Infect Dis, 2023, 76(1): 103-112. doi:10.1093/cid/ciac453.
[21]	Dedrick RM, Guerrero-Bustamante CA, Garlena RA, et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med, 2019, 25(5): 730-733. doi:10.1038/s41591-019-0437-z.
[22]	Nick JA, Dedrick RM, Gray AL, et al. Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection. Cell, 2022, 185(11): 1860-1874.e12. doi:10.1016/j.cell.2022.04.024.
[23]	Ong T, Ramsey BW. Cystic Fibrosis: A Review. JAMA, 2023, 329(21): 1859-1871. doi:10.1001/jama.2023.8120. pmid: 37278811
[24]	Tiddens HAWM, Chen Y, Andrinopoulou ER, et al. The effect of inhaled hypertonic saline on lung structure in children aged 3-6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial. Lancet Respir Med, 2022, 10(7): 669-678. doi:10.1016/S2213-2600(21)00546-4.

治疗时间	用药方案	痰脓肿分枝杆菌培养结果及时间
2021/11—2021/12	静脉滴注亚胺培南(1g/次,2次/d)和阿米卡星(0.4g/次,1次/d);口服利奈唑胺(0.6g/次)和阿奇霉素(0.5g/次),均为1次/d	阳性(2021/11)
2021/12—2022/06	阿米卡星(0.6g/次)雾化,口服利奈唑胺(600mg/次)、阿奇霉素(0.5g/次)、莫西沙星(0.4g/次),均为1次/d	阴性(2022/02)
2022/06—2022/08	阿米卡星(0.6g/次)雾化,口服阿奇霉素(0.5g/次)和莫西沙星(0.4g/次),均为1次/d	阴性(2022/06) 阳性(2022/08)
2022/09—2023/07	阿米卡星(0.6g/次)雾化;口服多西环素(0.1g/次,2次/d)、复方新诺明(0.8g/次,2次/d)和莫西沙星(0.4g/次,1次/d)	阴性(2022/12、2023/02、 2023/06、2023/09)

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

References 24

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zeng Wenmei, Wu Sulong, Liu Zhuofan, Yuan Long, Chen Bilin, Rong Yan. Analysis of all-night evaluation indexes and predictors of cardiovascular risk in patients with obstructive sleep apnea-hypopnea syndrome [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 1-7.
[2]	Yang Yarui, Guo Xujun, Wei Wei, He Juan, Li Shengbin, Zhong Tao, Gao Wanling, Liu Shoujiang, Liu Shengyuan. Awareness and factors associated with chronic obstructive pulmonary disease among permanent residents aged ≥40 years old in Nanshan District, Shenzhen [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(6): 517-525.
[3]	Yunnan Provincial Clinical Medical Center for Infectious Disease, Professional Committee of Respiratory Medicine of Yunnan Hospital Association, Professional Committee of Early Diagnosis and Treatment of Pulmonary Nodules of Kunming Medical Association. Expert consensus on standardized diagnosis and treatment of pulmonary nodules [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(5): 388-397.
[4]	Yuan Lirong, Yang Qinglong, Li Yuling, Li Lin, Deng Shasha, Li Shuhua. Effect of computerized cognitive behavioral therapy in the management of symptom cluster in patients with chronic obstructive pulmonary disease: a randomized controlled trial [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(5): 476-483.
[5]	Zhao Ruina, Li Shuhua, Cui Xiaohong, Gong Qiaoqiao, Pei Junli, Yuan Lirong. Distribution characteristics and influencing factors of pathogens in ventilator associated pneumonia [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(4): 305-310.
[6]	. [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(3): 187-190.
[7]	Wang Lin, Zhang Zinan. Current status and prospects of pulmonary rehabilitation in patients with chronic obstructive pulmonary disease [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(3): 191-196.
[8]	Zheng Xiaoxia, Zhu Xiaoxiao, Wu Yifan, Gu Fen. The correlation between symptom burden and quality of life in patients with chronic obstructive pulmonary disease [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(3): 207-211.
[9]	Pan Qiong, Tian Yayuan, Tong Fei. Effect of early limb active exercise on incidence of pulmonary embolism among patients received lung cancer surgery [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(3): 212-218.
[10]	Zhu Xiaoxiao, Tian Yayuan, Wang Pengfei, Huang Jiali, Gu Fen. Application effect and safety analysis of a sputum splash prevention device [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(3): 225-229.
[11]	Wu Shaozhu, Yu Xueying, Luo Yuanrong, Liu Yanfei, Ke Caixia. The effectiveness of multidisciplinary graded collaborative management on swallowing screening and intervention in patients with chronic obstructive pulmonary disease [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(3): 230-235.
[12]	Zhang Yidan, Gu Fen, Li Nannan. Current status and nursing research progress of long-term oxygen therapy for patients with chronic obstructive pulmonary disease [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(3): 249-253.
[13]	Qu Chunjin, Peng Jiayi, Liu Xinyi, Xiao Guanchen, Gu Fen, Li Nannan. Research progress on continuous nursing of patients with chronic obstructive pulmonary disease [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(3): 254-259.
[14]	Xu Siyun, Lu Nihong. Research progress of respiratory system injury caused by novel coronavirus [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(3): 267-272.
[15]	Yuan Yonglong, Li Huimei, Ma Dedong. Metagenomic next-generation sequencing assisted in the diagnosis of psittacosis: a case report and literature review [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(2): 113-119.